Компания Option Care выбрана в качестве предпочитаемого поставщика инфузионной ИГ-терапии на дому для участников организации Independence Blue Cross
By: Option Care
March 1, 2016
Effective March 1, 2016, Option Care Enterprises, Inc. will be a preferred provider of intravenous and subcutaneous immunoglobulin (IVIG/SCIG) drugs provided in the home[*]Members can continue to receive IVIG/SCIG from home infusion vendors currently owned by a hospital or health system participating in the Independence Blue Cross provider network. for members covered by affiliates of Independence Blue Cross. [*]Independence Blue Cross is a holding company and is not the name, or in the name, of an entity that “writes insurance.
As one of the nation’s largest providers of home and alternate treatment site infusion services, Option Care’s specially trained nurses and pharmacists provide high-quality, high-touch clinical support to patients treated for complex conditions, including those receiving IG. Option Care IG patients report very high levels of satisfaction — 98 percent — with Option Care’s in-home visits and ongoing support calls to help them manage their conditions.[*]Option Care Enterprises, Inc. Data on file 2016.
IG therapy is prescribed to patients with immune system-related conditions, including primary immunodeficiency disorders (the body’s immune system doesn’t function properly), autoimmune disorders (the body attacks itself) and other conditions that benefit from the treatment. IG therapy is delivered one of two ways: IVIG is infused through a vein, and SCIG is delivered into the fatty tissue just below the skin. Including IVIG and SCIG, Option Care manages more than 55,000 IG infusions each year.[*]Orange J, Kirkham H, Ayer G, et al. Improved clinical outcomes for patients receiving immunoglobulin therapy through specialty pharmacy or home infusion services. Paper presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2015 Annual Scientific Meeting: Nov 5-9, 2015; San Antonio.
В недавнем беспрецедентном исследовании пациенты Option Care на домашней иммуноглобулинотерапии, за которыми наблюдали самым тщательным образом и контролировали клинические показатели, демонстрировали лучшие результаты по сравнению с пациентами из большой национальной базы данных, получавшими ИГТ в других условиях.
Option Care предлагает все доступные препараты иммуноглобулина, а штат компании, включающий более 1700 клинических специалистов, в том числе медработников и фармацевтов, специально обученных проведению внутривенной/подкожной иммуноглобулинотерапии, осуществляет высококачественный уход, включая составление персонализированных планов лечения пациентов, клинический мониторинг каждого сеанса инфузионной терапии и комплексное обучение и информирование пациентов и ухаживающих за ними лиц.
You might also be interested in:
Regence and Option Care Health Partner to Provide Options for High-Risk Patients Who Rely on Infusion Therapy
Ensuring Patient Safety and Continuity of Care is Key During COVID-19 Public Health Crisis as Hospitals Face Unprecedented Challenges BANNOCKBURN, Ill., April 22, 2020 – Regence and Option Care Health, Inc. (“Option Care Health”) (NASDAQ: OPCH) today announced an expanded partnership to ease access to care and provide additional options for high-risk patients who rely on […]
Option Care Health Selected as Preferred Pharmacy Partner To Prepare and Distribute Breakthrough Cancer Therapy
First surgery-free treatment option for rare, difficult-to-treat urinary tract cancer requires complex clinical protocol BANNOCKBURN, Ill., May 21, 2020 (GLOBE NEWSWIRE) — Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, has been selected by UroGen Pharma (NASDAQ: URGN) as a preferred […]